| 1 | 100 mg elx/50 mg tez/75 mg iva fixed dose combination | - | - | - | - | 2991件: 299 💬 | 
| 2 | 50 mg elx/25 mg tez/37.5 mg iva fixed dose combination | - | - | - | - | 2991件: 299 💬 | 
| 3 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | Clarithromycin | 3件: D00276D00276, D00278D00278, D00424D00424 💬 | - | - | 0961件: 96 💬 | 
| 4 | Calcium and vitamin d combination | Calcium | - | - | - | 0131件: 13 💬 | 
| 5 | Combination | - | - | - | - | 0461件: 46 💬 | 
| 6 | Combination antiviral therapy | - | - | - | - | 0931件: 93 💬 | 
| 7 | Combination fish oil and borage seed oil | Fish oil | - | - | - | 0461件: 46 💬 | 
| 8 | Combination injection of epo and g-csf | Filgrastim | 1件: D03235D03235 💬 | CSF3R1件: CSF3R 💬 | Cytokine-cytokine receptor interaction5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer | 0061件:  6  💬 | 
| 9 | Combination of a single dose anti-cd20 antibody and bortezomib | Bortezomib | 1件: D03150D03150 💬 | PSMB51件: PSMB5 💬 | Alzheimer disease8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 0611件: 61 💬 | 
| 10 | Combination of fish oil and colesevelam | Colesevelam | 2件: D03582D03582, D07743D07743 💬 | - | - | 2601件: 260 💬 | 
| 11 | Combination of minocycline and mtx or mtx alone | Minocycline | 2件: D00850D00850, D05045D05045 💬 | - | - | 0461件: 46 💬 | 
| 12 | Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine | Azathioprine | 12件: D00238D00238, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D02994D02994, D03033D03033 💬 | MS4A12件: MS4A1, NR3C1 💬 | Hematopoietic cell lineage2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction | 0351件: 35 💬 | 
| 13 | Combination of thrombopoietin mimetic and cyclosporin a | Cyclosporine | 1件: D00184D00184 💬 | PPP3CA5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 0601件: 60 💬 | 
| 14 | Combination oral budesonide and rectal hydrocortisone | Budesonide | 2件: D00088D00088, D00246D00246 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0971件: 97 💬 | 
| 15 | Combination product (natpara) and drug or supplements [disease and drug registry] | - | - | - | - | 2351件: 235 💬 | 
| 16 | Combination product:  device: axially oscillating sphere dry powder inhaler (aos dpi) | - | - | - | - | 0861件: 86 💬 | 
| 17 | Combination product: active treatment with dual therapy | - | - | - | - | 0021件:  2  💬 | 
| 18 | Combination product: beclomethasone dipropionate in addition to mc-evoo | Beclomethasone dipropionate | 2件: D00689D00689, D07495D07495 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0971件: 97 💬 | 
| 19 | Combination product: beclomethasone dipropionate in addition to refined oil | Beclomethasone dipropionate | 2件: D00689D00689, D07495D07495 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0971件: 97 💬 | 
| 20 | Combination product: belimumab | Belimumab | 1件: D03068D03068 💬 | TNFSF13B1件: TNFSF13B 💬 | Cytokine-cytokine receptor interaction4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis | 0491件: 49 💬 | 
| 21 | Combination product: goldic serum | - | - | - | - | 0701件: 70 💬 | 
| 22 | Combination product: hyperbaric oxygen therapy- | Oxygen | 1件: D00003D00003 💬 | - | - | 2261件: 226 💬 | 
| 23 | Combination product: implantable system for remodulin (treprostinil) | Treprostinil | 1件: D06213D06213 💬 | PTGIR1件: PTGIR 💬 | Neuroactive ligand-receptor interaction3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 0861件: 86 💬 | 
| 24 | Combination product: l-dopa 140 mg | Levodopa | 1件: D00059D00059 💬 | DRD15件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 0061件:  6  💬 | 
| 25 | Combination product: l-dopa 35 mg | Levodopa | 1件: D00059D00059 💬 | DRD15件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 0061件:  6  💬 | 
| 26 | Combination product: l-dopa 70mg | Levodopa | 1件: D00059D00059 💬 | DRD15件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway | 0061件:  6  💬 | 
| 27 | Combination product: l-dopa 70mg/carbidopa 7mg | Carbidopa | 2件: D00059D00059, D00558D00558 💬 | DDC6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | Alcoholism16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway | 0061件:  6  💬 | 
| 28 | Combination product: mavrilimumab | Mavrilimumab | 1件: D09930D09930 💬 | CSF2RA1件: CSF2RA 💬 | Cytokine-cytokine receptor interaction4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer | 0411件: 41 💬 | 
| 29 | Combination product: methotrexate | Methotrexate | 2件: D00142D00142, D02115D02115 💬 | DHFR2件: DHFR, DHFR2 💬 | Antifolate resistance5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 0461件: 46 💬 | 
| 30 | Combination product: nd0612 solution for sc infusion | - | - | - | - | 0061件:  6  💬 | 
| 31 | Combination product: ofatumumab with ai | Ofatumumab | 1件: D09314D09314 💬 | MS4A11件: MS4A1 💬 | Hematopoietic cell lineage1件: Hematopoietic cell lineage | 0131件: 13 💬 | 
| 32 | Combination product: ofatumumab with prf | Ofatumumab | 1件: D09314D09314 💬 | MS4A11件: MS4A1 💬 | Hematopoietic cell lineage1件: Hematopoietic cell lineage | 0131件: 13 💬 | 
| 33 | Combination product: prp combined magnovision | - | - | - | - | 0901件: 90 💬 | 
| 34 | Combination product: transcon pth | - | - | - | - | 2351件: 235 💬 | 
| 35 | Combination product: treprostinil via implanted pump | Treprostinil | 1件: D06213D06213 💬 | PTGIR1件: PTGIR 💬 | Neuroactive ligand-receptor interaction3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction | 0861件: 86 💬 | 
| 36 | Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator | Acetate | 2件: D00088D00088, D00165D00165 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0971件: 97 💬 | 
| 37 | Combination steroid | - | - | - | - | 0461件: 46 💬 | 
| 38 | Combination therapy with vigabatrin and prednisolone | Prednisolone | 9件: D00472D00472, D00535D00535, D00980D00980, D00981D00981, D00982D00982, D01239D01239, D01998D01998, D02156D02156, D03301D03301 💬 | ABAT2件: ABAT, NR3C1 💬 | Alanine, aspartate and glutamate metabolism8件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism | 1451件: 145 💬 | 
| 39 | Continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis) | - | - | - | - | 2651件: 265 💬 | 
| 40 | Conventional dmard combination | - | - | - | - | 0461件: 46 💬 | 
| 41 | Cytotoxic combination | - | - | - | - | 0561件: 56 💬 | 
| 42 | Device: abatacept combination product (acp) | Abatacept | 1件: D03203D03203 💬 | CD802件: CD80, CD86 💬 | Allograft rejection12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis | 0461件: 46 💬 | 
| 43 | Eflornithine plus nifurtimox combination therapy | Eflornithine | 2件: D00833D00833, D07883D07883 💬 | ODC11件: ODC1 💬 | Arginine and proline metabolism3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways | 0651件: 65 💬 | 
| 44 | Ezetimibe+simvastatin drug combination | Ezetimibe | 2件: D00434D00434, D01966D01966 💬 | HMGCR2件: HMGCR, NPC1L1 💬 | AMPK signaling pathway5件: AMPK signaling pathway, Bile secretion, Fat digestion and absorption, Metabolic pathways, Terpenoid backbone biosynthesis | 0491件: 49 💬 | 
| 45 | Fixed dose combination ciprofloxacin/celecoxib | Celecoxib | 3件: D00186D00186, D00567D00567, D02216D02216 💬 | PTGS21件: PTGS2 💬 | Alzheimer disease22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 0021件:  2  💬 | 
| 46 | Infliximab and azathioprine combination at week 0 | Azathioprine | 3件: D00238D00238, D02598D02598, D03033D03033 💬 | TNF1件: TNF 💬 | AGE-RAGE signaling pathway in diabetic complications65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 0961件: 96 💬 | 
| 47 | Infliximab and azathioprine combination at week 14 | Azathioprine | 3件: D00238D00238, D02598D02598, D03033D03033 💬 | TNF1件: TNF 💬 | AGE-RAGE signaling pathway in diabetic complications65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 0961件: 96 💬 | 
| 48 | Lum/iva fixed-dose combination | - | - | - | - | 2991件: 299 💬 | 
| 49 | Lumacaftor plus ivacaftor combination | Ivacaftor | 2件: D09916D09916, D10134D10134 💬 | CFTR1件: CFTR 💬 | ABC transporters8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway | 2991件: 299 💬 | 
| 50 | Lumacaftor, ivacaftor drug combination | Ivacaftor | 2件: D09916D09916, D10134D10134 💬 | CFTR1件: CFTR 💬 | ABC transporters8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway | 2991件: 299 💬 | 
| 51 | Nebulized combination ipratropium bromide with salbutamol | Ipratropium | 2件: D02147D02147, D02212D02212 💬 | ADRB26件: ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | Adrenergic signaling in cardiomyocytes17件: Adrenergic signaling in cardiomyocytes, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway | 0861件: 86 💬 | 
| 52 | Nifurtimox-eflronithine combination treatment (nect) | Nifurtimox | 1件: D00833D00833 💬 | - | - | 0651件: 65 💬 | 
| 53 | Nutraceutical combination | - | - | - | - | 0961件: 96 💬 | 
| 54 | Other: ibuprofen and isosorbide dinitrate combination | Ibuprofen | 6件: D00126D00126, D00347D00347, D00516D00516, D01122D01122, D04490D04490, D06606D06606 💬 | PTGS12件: PTGS1, PTGS2 💬 | Alzheimer disease23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway | 1131件: 113 💬 | 
| 55 | Other: iv steroids combination alone | - | - | - | - | 0411件: 41 💬 | 
| 56 | Part 2, jm-010 combination group a | - | - | - | - | 0061件:  6  💬 | 
| 57 | Part 2, jm-010 combination group b | - | - | - | - | 0061件:  6  💬 | 
| 58 | Ph-combination therapy | - | - | - | - | 0862件: 86, 88 💬 | 
| 59 | Piperacillin-tazobactam combination product | Piperacillin | 4件: D00466D00466, D00660D00660, D02251D02251, D08380D08380 💬 | - | - | 2991件: 299 💬 | 
| 60 | Rapamycin-calcitriol combination | Calcitriol | 2件: D00129D00129, D00753D00753 💬 | MTOR2件: MTOR, VDR 💬 | AMPK signaling pathway54件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Mineral absorption, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Tuberculosis, Type II diabetes mellitus, mTOR signaling pathway | 1581件: 158 💬 | 
| 61 | Rhtpo in combination with rituximab | Recombinant Human Thrombopoietin | 1件: D02994D02994 💬 | MS4A11件: MS4A1 💬 | Hematopoietic cell lineage1件: Hematopoietic cell lineage | 0631件: 63 💬 | 
| 62 | Tadalafil and ambrisentan upfront combination therapy | Ambrisentan | 2件: D02008D02008, D07077D07077 💬 | EDNRA2件: EDNRA, PDE5A 💬 | Calcium signaling pathway9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway | 0512件: 51, 86 💬 | 
| 63 | Tocilizumab and iv steroids combination | Tocilizumab | 1件: D02596D02596 💬 | IL6R1件: IL6R 💬 | Coronavirus disease - COVID-1912件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor | 0411件: 41 💬 | 
| 64 | Triple combination therapy | - | - | - | - | 2991件: 299 💬 | 
| 65 | Ursodeoxycholic acid combination of immunosuppressive agents | Ursodeoxycholic acid | 1件: D00734D00734 💬 | NR1H41件: NR1H4 💬 | Bile secretion1件: Bile secretion | 0932件: 93, 95 💬 | 
| 66 | Von willebrand factor and coagulation factor viii in combination | Beroctocog alfa | - | - | - | 2881件: 288 💬 | 
| 67 | Vx-661 plus ivacaftor combination | Ivacaftor | 1件: D09916D09916 💬 | CFTR1件: CFTR 💬 | ABC transporters8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway | 2991件: 299 💬 |